Amgen could compete with established leaders in obesity, says analyst
Earlier this month US biotech major Amgen (Nasdaq: AMGN) presented at the JP Morgan’s 42nd Annual Healthcare Conference, highlighting its pillars of business. One of these pillars was the general medicine franchise, which entailed the obesity space.
The company has two promising pipeline agents in development for obesity that address the unmet needs of improved efficacy, faster weight loss, and potentially better maintenance of weight loss, with the possibility of monthly dosing. This may potentially set Amgen on a trajectory to compete with established leaders in the obesity space, says pharma analytics company GlobalData.
GlobalData’s report “ Obesity: Seven-Market Drug Forecast and Market Analysis,” which explores marketed and late-stage pipeline pharmacotherapies in the obesity space, reveals that in the US, the obesity market is anticipated to reach a value of $27.6 billion by 2031.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze